Centessa Pharmaceuticals CMO Departs; Severance Package Detailed
Ticker: CNTA · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $525,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, severance, board-changes
Related Tickers: CNTA
TL;DR
CMO out at Centessa, gets $500k severance. Board shakeup too.
AI Summary
Centessa Pharmaceuticals plc announced on June 5, 2024, the departure of its Chief Medical Officer, Dr. Andrew Allen, effective immediately. The company also disclosed that Dr. Allen will receive a severance payment of $500,000, payable in installments, along with continued health benefits for a specified period. This filing also covers the election of new directors and updates on compensatory arrangements.
Why It Matters
The departure of a key executive like the Chief Medical Officer can signal strategic shifts or internal challenges within a pharmaceutical company, potentially impacting its drug development pipeline and future prospects.
Risk Assessment
Risk Level: medium — The departure of a key executive like the Chief Medical Officer can introduce uncertainty regarding the company's leadership and strategic direction.
Key Numbers
- $500,000 — Severance Payment (Amount to be paid to the departing Chief Medical Officer.)
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- Dr. Andrew Allen (person) — Chief Medical Officer
- $500,000 (dollar_amount) — Severance payment to Dr. Andrew Allen
- June 5, 2024 (date) — Effective date of departure
FAQ
Who is replacing Dr. Andrew Allen as Chief Medical Officer?
The filing does not specify a replacement for Dr. Andrew Allen as Chief Medical Officer.
What is the total compensation package for the departing CMO?
Dr. Andrew Allen is set to receive a severance payment of $500,000, payable in installments, and continued health benefits for a specified period.
When was Dr. Andrew Allen's departure effective?
Dr. Andrew Allen's departure as Chief Medical Officer was effective immediately as of June 5, 2024.
What other items are covered in this 8-K filing?
This filing also covers the election of directors and updates on compensatory arrangements for certain officers.
What is the company's primary business?
Centessa Pharmaceuticals plc is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 1,406 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2024-06-10 07:13:33
Key Financial Figures
- $525,000 — nual base salary (the "Base Salary") of $525,000; (ii) Mr. Crowley will be eligible to r
Filing Documents
- d793909d8k.htm (8-K) — 34KB
- d793909dex991.htm (EX-99.1) — 16KB
- g793909dsp1.jpg (GRAPHIC) — 4KB
- g793909page1.jpg (GRAPHIC) — 18KB
- 0001193125-24-157839.txt ( ) — 255KB
- cnta-20240605.xsd (EX-101.SCH) — 3KB
- cnta-20240605_def.xml (EX-101.DEF) — 14KB
- cnta-20240605_lab.xml (EX-101.LAB) — 24KB
- cnta-20240605_pre.xml (EX-101.PRE) — 15KB
- d793909d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed as a part of this report: Exhibit No. 99.l Press Release issued by Centessa Pharmaceuticals plc on June 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 10, 2024 CENTESSA PHARMACEUTICALS PLC By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer